BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30356164)

  • 1. Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation.
    Rivera D; Bastida JM; Lopez-Corral L; Sanchez-Guijo F; Cabrero M; Martin A; Perez E; Lopez-Parra M; Avendaño A; Veiga A; Baile M; Arratibel N; Carrillo J; Vazquez L; Caballero MD; Gonzalez-Porras JR
    Bone Marrow Transplant; 2019 May; 54(5):757-761. PubMed ID: 30356164
    [No Abstract]   [Full Text] [Related]  

  • 2. Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children.
    Masetti R; Vendemini F; Quarello P; Girardi K; Prete A; Fagioli F; Pession A; Locatelli F
    Pediatr Blood Cancer; 2020 May; 67(5):e28208. PubMed ID: 32065469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.
    Bento L; Bastida JM; García-Cadenas I; García-Torres E; Rivera D; Bosch-Vilaseca A; De Miguel C; Martínez-Muñoz ME; Fernández-Avilés F; Roldán E; Chinea A; Yáñez L; Zudaire T; Vaz CP; Espigado I; López J; Valcárcel D; Duarte R; Cabrera R; Herrera C; González-Porras JR; Gutiérrez A; Solano C; Sampol A;
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1825-1831. PubMed ID: 31152794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation.
    Tanaka T; Inamoto Y; Yamashita T; Fuji S; Okinaka K; Kurosawa S; Kim SW; Tanosaki R; Fukuda T
    Biol Blood Marrow Transplant; 2016 May; 22(5):919-24. PubMed ID: 26785333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children.
    Li S; Wu R; Wang B; Fu L; Zhu G; Zhou X; Ma J; Zhang L; Qin M
    J Pediatr Hematol Oncol; 2019 Jan; 41(1):38-41. PubMed ID: 30080752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experience.
    Kilic Gunes E; Yigit Kaya S; Yaman F; Yeniay MK; Vural K; Comert M; Sevindik OG; Andic N; Dagdas S; Nizam Ozen I; Kaynar L; Yavasoglu F; Ozet G; Karakus V; Ayli M
    Leuk Res; 2024 May; 140():107484. PubMed ID: 38520796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Has Eltrombopag eliminated the need to use allogeneic HSCT in first line treatment of pediatric aplastic anemia?
    Huan Ng C; Jang-Milligan F; Schultz KR
    Pediatr Hematol Oncol; 2021 Aug; 38(5):417-419. PubMed ID: 34157932
    [No Abstract]   [Full Text] [Related]  

  • 8. Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation.
    Yuan C; Boyd AM; Nelson J; Patel RD; Varela JC; Goldstein SC; Ahmad S; Zhu X; Mori S
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1320-1324. PubMed ID: 30710685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia.
    Paul S; Jain N; Ferrajoli A; O'Brien S; Burger J; Keating M; Wierda W
    Br J Haematol; 2019 May; 185(3):606-608. PubMed ID: 30406944
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification of anti-thrombopoietin receptor antibody in prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation treated successfully with eltrombopag.
    Fujimi A; Kamihara Y; Hashimoto A; Kanisawa Y; Nakajima C; Hayasaka N; Yamada S; Okuda T; Minami S; Ono K; Iyama S; Kato J
    Int J Hematol; 2015 Oct; 102(4):471-6. PubMed ID: 25964100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecule of the month. Eltrombopag.
    Drug News Perspect; 2008; 21(6):344. PubMed ID: 18836592
    [No Abstract]   [Full Text] [Related]  

  • 12. Eltrombopag induces major non-toxic hypersiderraemia.
    Caillon H; Peterlin P; Chevallier P; Guillaume T; Lebourgeois A; Garnier A; Ropert-Bouchet M; Dejoie T
    Br J Haematol; 2019 Jul; 186(2):365-366. PubMed ID: 30873599
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study.
    Kawaguchi T; Komori A; Seike M; Fujiyama S; Watanabe H; Tanaka M; Sakisaka S; Nakamuta M; Sasaki Y; Oketani M; Hattori T; Katsura K; Sata M
    J Gastroenterol; 2012 Dec; 47(12):1342-51. PubMed ID: 22674141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eltrombopag named patient programme for patients with chronic immune thrombocytopenia.
    Scully M; Kaczmarski R; Myers B; Collins R; Emohare O; Bolton-Maggs PH
    Br J Haematol; 2012 Apr; 157(2):259-60. PubMed ID: 22091659
    [No Abstract]   [Full Text] [Related]  

  • 15. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
    Svensson T; Chowdhury O; Garelius H; Lorenz F; Saft L; Jacobsen SE; Hellström-Lindberg E; Cherif H
    Eur J Haematol; 2014 Nov; 93(5):439-45. PubMed ID: 24853277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond.
    Taylor A; Westwood JP; Laskou F; McGuckin S; Scully M
    Br J Haematol; 2017 May; 177(3):475-480. PubMed ID: 28295201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploidentical peripheral blood stem cell transplantation: a single-center experience.
    Yan F; Lu N; Gu Z; Huang W; Wang S; Gao X; Dou L; Li F; Wang L; Li M; Liu D; Gao C
    Ann Hematol; 2022 Feb; 101(2):397-408. PubMed ID: 34735613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide.
    Chawla SP; Staddon A; Hendifar A; Messam CA; Patwardhan R; Kamel YM
    BMC Cancer; 2013 Mar; 13():121. PubMed ID: 23497336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation.
    Pecci A; Barozzi S; d'Amico S; Balduini CL
    Thromb Haemost; 2012 Jun; 107(6):1188-9. PubMed ID: 22398565
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
    González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
    Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.